Gines's mailing address filed with the SEC is C/O 700 TECHNOLOGY DRIVE, THIRD FLOOR, , PITTSBURGH, PA, 15219.
Over the last 5 years, insiders at NeuBase Therapeutics have traded over 713,184$ worth of NeuBase Therapeutics stock and bought 177,514 units worth 548,788$ . The most active insiders traders include Dov A Md Goldstein、Dietrich A Stephan、Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of 37,929$. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth 375,652$.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
NeuBase Therapeutics executives and other stock owners filed with the SEC include: